Device Trial Radar · NCT04976530
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Aug 31, 2021
Primary completion
Aug 7, 2023
Study completion Aug 7, 2023
Sponsor
- Lead sponsor
- CytoSorbents, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB).
Conditions
- Hemorrhage, Surgical
- Blood Loss, Surgical
- Blood Loss, Postoperative
- Hemorrhage Postoperative
Interventions
DrugSorb-ATR systemDevice
Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
Sham comparatorDevice
Sham comparator in similar position to the investigative device, but NOT integrated into the cardiopulmonary (CPB) circuit
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) PopulationTime frame: Through the first 48hrs post-operation
3 more outcomes with a free account
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Davis Medical Center
Sacramento, California
28 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.